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9:45 
PROGNOSTIC SIGNIFICANCE OF HOLTER MONITORING 
IN APPARENTLY HEALTHY OLDER SUBJECIS 
and I-Iarold L. Kennedy, Gerontology Research 
Center, National Institute on Aging, NIH, Baltimore, MD 
The long-term prognostic significance of frequent or complex 
ectopic beats on ambulatory ECG (AECG) in apparently healthy 
o!der subjects is unkxwn. We have therefore followed 98 
volunteers from the Baltimore Longitudinal Study of Aging -who 
were 60-85 years old and free of cardiac disease by history, 
physical examination and maximal treadmill testing at the time of 
AECG between 1978 and 1980. Over a mean followup period of 
10 years, coronary events (CE) have developed in 10 subjects: 
angina pectoris in 5, myocardial infarction in 2, and sudden 
cardiac death in 3. The prevalence of the following arrhythmias 
did not differ significantly between subjects who developed CE 
and those who did not, respectively; 230 supraventricular ectopic 
beats (SVEB) in any hour, 40% vs 20%; paroxysmal atria1 
tachycardia (PAT), 20% vs 13%; ~30 ventricular ectopic beats 
(VEB) in any hour, 10% vs 13%; 2100 VEB in 24 hours, 20% 
vs 17%; or Lawn Grade 4 VEB, 20% vs 13%. The mean 24 
hour heart rate (74.7 vs 71.7/min) as well as the maximum (114.9 
vs 111.3/min) and minimum heart rate (SO.9 vs 52.8/min) also did 
not differ between the respective groups. Although flat or 
downsloping ST segment depression ~1.0 mm was seen in only 
5 subjects, CE occurred in 2 of these 5 (40%) vs only 8 (8%) of 
93 subjects without such ST segment changes. Thus, neither 
WEB nor VEB on AECG predict the development of future CE 
in clinically healthy older subjects; silent ischemia, although 
infrequent, may be the most specific AECG predictor of future 
CE in such a low risk population, 
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8:30 
DetectIon of Acute Myocardlal Infarction in PaUents with Non- 
D&gnostic ECGs: Use of Serial CK-MB Sampltng in the 
Emergency Department 
W. &Ian Gtbler, Jerr& R Hedges. Gq P. Young, Larxy M. 
EL!%& Emegency Medicine Cardiac Research Group 
Untverslty of Cincinnati. CIncInnaU. Ohio 
Se&l CK-MB saxnpllng was used in the emegency department 
(ED1 to determine if patients wtth acute myoeardtal tnfarctlon 
WI1 and non-dlagnostk ECGs (NDECGs) could be identified. 
Seven hundred and nineteen patients hospital&cd for possible 
ischemtc chest pain were evaluated at eight academtc medical 
center hospitals. CK-MB levels were determined on ED 
admlsslon and 1.2. and 9 hours after presentation. PaUents 
with one CK-MB level ~7 rig/ml or rising CK-IKE levels over the 
three hour time interval were conaidend to have a Dositive ED 
enzyme &ucly using a new rapid immunochemtcal kethod 
mdanm ICON QSR CK-MB assay, Hybrltech. Inc.) requlrlng 
ten minutes to perform. ECGs were considered to be diagnostic 
for AM1 if 1 mtlllmeter of m-segment elevation was present in 
two or more elcctrlcally contiguous leads. The development of 
new Q-waves or standard fn-hospital enzyme changes 
cot&rned AhlI patlents. Of 719 patients, 128 (17.8%) were 
considered to have AM1 with 75 (58.5%) having NDECGs. Of 
paUents with NDECGs, 62 (82.89b sensitivity) had a positive 
setial CK-MB study within 3 hours of ED presentation 
bpeclfWy 93.4%. negative pndlctive value 94.6%). 
Comblnlng serial CK-MB samplhg results In NDECG patients 
and pattents with a diagnosuc ECG demonstrated a 91.3% 
sensttMty for detecting AM1 in the ED. 
ConclusIonS: 8erial CK-MB determinations in the ED 
may 11 help prevent the ED discharge of patients with AM1 
and a NDECG: 21 tmpruve the disposttton of paUents with 
AMI and NRECGs to intensive care &tin@; and 
3) potentially identify patients wltb AMI and a NDECGs 
for txcatment with thrombolytk therapy. 
8:45 
CLINICAL ASSESSMENT OF A 
IMMUNOASSAY SPECIFIC 
TROPONIN-I 
ITPVE 
AN C 
Kazuhiko Nishida, Jouji Naito. Takayoshi 
Adachi, Kazuo Honda, Kazuhisa Kodama. 
Osaka Police Hospital, Osaka, Japan. 
A sensitive human cardiac troponin-I (Tn-I) specific enzyme 
immunoassay with the use of monoclonal antibodies was 
developed and evaluated as a selective diagnostic test for acute 
myocardial infarction (AM!) and unstable angina (UA). The 
assay was completed within 30 minutes and had a sensitivity of 
0.5 pg/L. The cross reactivity with skeletal muscle Tn.1 was 
less than 0.01%. Tn.1 was not detected in serum from 150 
normals and 26 Pts wi:h skeletal muscle damage, whose 
creatine kinase (CK) activities ranged from 2.500 IO lg.000 U/L. 
The serial Tn.1 levels were measured after admission in 52 PU 
with AMI. The significant elevations of serum TD-I level (z-1.0 
pg/L> were shown in 62% of pts at 1 hour, 758 at 4 hours and 
87% at 8 hours after the onset of chest pain. CK-M 
were elevated in 0% at 1 hour, 24% at 4 hours and g78 at 8 
hours. Serum Tn.1 level reached a mean peak level of 127 pg/L 
(range 45 to 256 pg/L) at 20 hours, and remained above normal 
for $1~ to 8 IO IO days following infarction. The interval during 
which Tn.1 and CK-MB were elevated abnormally in all 
patients were 12 hours to 5 days and 12 hrs to 48 hrs after the 
onset. respectively. Thus Tn.1 was a specific marker of 
myocardial cell necrosis and elevated during early and late 
pe.riod of AMI. Fourteen of 25 Pts with UA had elevated Tn.1 on 
admission. Complications occurred or urgent interventions 
were required in 10 pus of Tn.1 positive pts, however none of 
Tn.1 negative pts required urgent interventions or suffered 
f:om complications. . m The rapid sensitive assay for Tn-I was useful for 
early and late confirmation of AMI and may have prognostic 
value for marraging Pts with UA. 
9:ao 
Utility of Serial Creatine Kinase MB Levels 
During initial Assessment of Acute Chest Pain 
Michael M Marin Sam L Teichman ---) 
Lenox Hill Hospital, New York, NY 
Improved initial diagnostic accuracy in acute chest pain may 
help a) conserve hospital resources in pts without myocardial 
infarction( b) identify MI pts who may benefit from early 
intervention and c) avoid accidental discharge of pts with MI. 
Since newly available creatine kinase(CK) MB assays can 
provide results in cl hr, we determined if early, serial CK- 
MB levels could distinguish MI fror i non-MI chest pain. In 
pts admitted to the cardiac unit with ~12 hrs of pain, CK-MB 
was sampled at baseline(B), ie, hospital arrival and hourly for 
3 hrs (B+l hr, B+2, B+3). These CK-MB levels were analyzed 
for ability to predict the subsequent clinical diagnosis of MI. 
Of 313 eligible pts enrolled, index chest pain was due to MI 
in 70(22%). Of these 70, index ECG showed MI in 27(39%). 
CK-MB at B had a sensitivity(Sens)=76% and specificity(Spec) 
=72% for MI. The ability to identify MI by a rising CK-MB 
level using B plus l-3 subsequent samples was evaluated. 
Sens and Spec for MI diagnosis improved with each 
additional result to a maximum of 920/C & 96%, resp, with all 
4 samples. An algorithm usmg 2 samples, 2 hours apart (B & 
B+2) had an overall Sens=94% and Spec=91%; when pts with 
MI on index ECG were removed, Sens=90% and Spec=91%. 
Serial CK-MB sampling during triage of acute chest pain 
appears to identify most pts with and without MI within 2-4 
hrs of hospital arrival. Further studies are required to 
confirm this finding, to validate these algorithms and to 
evaluate the impact of this strategy on patient care. 
